Prologue SA
PAR:ALPRG
Prologue SA
PAR:ALPRG
Price:
0.238
EUR
-0.83%
Market Closed
Market Cap:
€23.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Prologue SA
PAR:ALPRG
|
FR |
|
S
|
Sif Holding NV
AEX:SIFG
|
NL |
|
K
|
KGHM Polska Miedz SA
OTC:KGHPF
|
PL |
|
Y
|
Yarrl SA
WSE:YRL
|
PL |
|
C
|
Celestica Inc
NYSE:CLS
|
CA |
|
S
|
Sta Lucia Land Inc
XPHS:SLI
|
PH |
|
D
|
Delfingen Industry SA
XBER:HBS
|
FR |
|
H
|
Hon Hai Precision Industry Co Ltd
LSE:HHPD
|
TW |
|
ISC Business Technology AG
F:I5Q1
|
CH |
|
Itausa SA
BOVESPA:ITSA4
|
BR |
|
S
|
Sun Life Financial Inc
NYSE:SLF
|
CA |
|
V
|
Vonovia SE
OTC:VNNVF
|
DE |
|
Baozun Inc
NASDAQ:BZUN
|
CN |
|
Alpen Co Ltd
TSE:3028
|
JP |
|
Asra Minerals Ltd
ASX:ASR
|
AU |
|
Diaceutics PLC
LSE:DXRX
|
UK |
|
H
|
Hefei Chipmore Technology Co Ltd
SSE:688352
|
CN |
|
S
|
SKF India Ltd
BSE:500472
|
IN |
|
V
|
Vrain Solution Inc
TSE:135A
|
JP |
|
Intergis Co Ltd
KRX:129260
|
KR |
|
EpiCentre Holdings Ltd
SGX:5MQ
|
SG |
|
I
|
Ikab Securities and Investment Ltd
BSE:514238
|
IN |
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
JP |
|
N
|
Novo Resources Corp
SWB:1NO
|
CA |
Cash Flow Statement
Cash Flow Statement
Prologue SA
Prologue SA
Currency: EUR
| Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Net Income |
0
|
(1)
|
(2)
|
1
|
(6)
|
(10)
|
(2)
|
3
|
9
|
|
| Depreciation & Amortization |
6
|
5
|
6
|
3
|
3
|
7
|
7
|
2
|
3
|
|
| Other Non-Cash Items |
3
|
1
|
4
|
0
|
7
|
7
|
0
|
1
|
(12)
|
|
| Change in Working Capital |
(1)
|
1
|
(1)
|
(2)
|
(2)
|
3
|
4
|
1
|
(5)
|
|
| Cash from Operating Activities |
8
N/A
|
6
-24%
|
7
+22%
|
3
-54%
|
2
-33%
|
6
+181%
|
9
+45%
|
6
-35%
|
(5)
N/A
|
|
| Investing Cash Flow | ||||||||||
| Capital Expenditures |
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(3)
|
(2)
|
(3)
|
(3)
|
|
| Other Items |
(1)
|
(1)
|
2
|
1
|
1
|
0
|
(0)
|
1
|
11
|
|
| Cash from Investing Activities |
(6)
N/A
|
(4)
+25%
|
(2)
+51%
|
(3)
-42%
|
(3)
-4%
|
(2)
+24%
|
(2)
+25%
|
(2)
-18%
|
8
N/A
|
|
| Financing Cash Flow | ||||||||||
| Net Issuance of Common Stock |
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
4
|
(1)
|
(6)
|
(3)
|
(4)
|
(3)
|
(4)
|
(3)
|
(1)
|
|
| Other |
(0)
|
0
|
(1)
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
4
N/A
|
(2)
N/A
|
(9)
-340%
|
(3)
+62%
|
(3)
-7%
|
(3)
+25%
|
(4)
-63%
|
(3)
+39%
|
(1)
+64%
|
|
| Change in Cash | ||||||||||
| Effect of Foreign Exchange Rates |
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
|
| Net Change in Cash |
6
N/A
|
(0)
N/A
|
(3)
-2 017%
|
(3)
+12%
|
(4)
-55%
|
1
N/A
|
3
+127%
|
1
-57%
|
2
+43%
|
|
| Free Cash Flow | ||||||||||
| Free Cash Flow |
4
N/A
|
2
-33%
|
3
+42%
|
(1)
N/A
|
(2)
-82%
|
4
N/A
|
8
+100%
|
3
-56%
|
(8)
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
